Covid-19 Vaccination in Nasopharyngeal Carcinoma Patients during COVID-19 Pandemic

Authors

  • Irnanda Warda Rizki Nasution Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • Farhat Farhat Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • Elvita Rahmi Daulay Departement of Radiology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.32734/ijnpc.v3i02.6323

Keywords:

Nasopharyngeal Carcinoma,, Vaccination, COVID-19, Adam Malik

Abstract

Introduction:

Nasopharyngeal carcinoma (NPC) is one kind of cancer that is the most common type of head and neck malignancy, arising from the posterior and lateral parts of the nasopharynx especially from torus tubarius or pharyngeal recess or the other name is Rosenmüller fossa. This shows significant differences from other head and neck cancers, clinical behavior, cause, epidemiology, treatment, as well as prognosis. Clinical trials of COVID-19 vaccines with better follow-up will provide useful data on vaccine advantages in patients receiving cancer treatment, due to the absence of complete data to determine the relationship between active oncology treatment and the power to induce immunity to COVID-19 using the vaccine.

Discussion:

The primary aim of vaccines is to produce stimulation by the antigen we desire in the presence of sufficient infection to elicit memory immunity with tolerable protection.[15] Due to the increasing frailty of cancer patients with infection as well as deaths from COVID-19, there is an urgent need to vaccinate patients with COVID-19 cancer. Various considerations for the protection and benefits that are expected to have an effect with treatment due to their standart management and changes in the immune system of patients with malignancies.

Conclusion

The COVID-19 vaccine, granted approved or permitted, will be considered the basic of prevention of this COVID-19 pandemic for patients with nasopharyngeal carcinoma. There are advantages and disadvantages about Covid-19 vaccine. Then, a quality direction on clinical trials of patients with cancer and COVID-19 vaccines becomes very attractive. Finally, comprehensive oncological care requires cancer patients to be prioritized for the COVID-19 vaccine

Downloads

Download data is not yet available.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018 Nov;68(6):394-424. DOI: https://doi.org/10.3322/caac.21492

[2] Chua, M.L.; Wee, J.T.; Hui, E.P.; Chan, A.T. Nasopharyngeal carcinoma. Lancet 2016, 387, 1012–1024. DOI: https://doi.org/10.1016/S0140-6736(15)00055-0

Barnes L, Eveson JW, Sidransky D, Reichart P, editors. Pathology and genetics of head and neck tumours. IARC; 2005.

Chow VL, Chan JY, Wong ST, Wei WI. Recommendations for surgical management of recurrent nasopharyngeal carcinoma during COVID‐19 pandemic. Laryngoscope Investigative Otolaryngology. 2020 Jun;5(3):468-72. DOI: https://doi.org/10.1002/lio2.417

Abdul-Jawad S, Baù L, Alaguthurai T, Del Barrio ID, Laing AG, Hayday TS, Monin L, Muñoz-Ruiz M, McDonald L, Quijorna IF, McKenzie D. Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients. Cancer Cell. 2021 Feb 8;39(2):257-75. DOI: https://doi.org/10.1016/j.ccell.2021.01.001

Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. New England Journal of Medicine. 2021 Jan 7;384(1):80-2. DOI: https://doi.org/10.1056/NEJMc2032195

Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, Arnthorsson AO, Helgason D, Bjarnadottir K, Ingvarsson RF, Thorsteinsdottir B. Humoral immune response to SARS-CoV-2 in Iceland. New England Journal of Medicine. 2020 Oct 29;383(18):1724-34. DOI: https://doi.org/10.1056/NEJMoa2026116

Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, Alanio C, Kuri-Cervantes L, Pampena MB, D’Andrea K, Manne S. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020 Sep 4;369(6508). DOI: https://doi.org/10.1126/science.abc8511

Hwang JK, Zhang T, Wang AZ, Li Z. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. Journal of hematology & oncology. 2021 Dec;14(1):1-1. DOI: https://doi.org/10.1186/s13045-021-01046-w

Haq EU, Yu J, Guo J. Frontiers in the COVID-19 vaccines development. Experimental hematology & oncology. 2020 Dec;9(1):1-6. DOI: https://doi.org/10.1186/s40164-020-00180-4

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet infectious diseases. 2021 Feb 1;21(2):181-92. DOI: https://doi.org/10.1016/S1473-3099(20)30843-4

Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet Infectious Diseases. 2021 Jan 1;21(1):39-51. DOI: https://doi.org/10.1016/S1473-3099(20)30831-8

Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine. 2020 Dec 10;383(24):2320-32. DOI: https://doi.org/10.1056/NEJMoa2026920

Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola JP, Liu J, Li Z, Chandrashekar A, Martinez DR. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 Aug 14;369(6505):806-11. DOI: https://doi.org/10.1126/science.abc6284

Liu MA. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines. 2019 Jun;7(2):37. DOI: https://doi.org/10.3390/vaccines7020037

Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nature reviews Drug discovery. 2018 Apr;17(4):261. DOI: https://doi.org/10.1038/nrd.2017.243

Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS, Prickett TD. mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. The Journal of Clinical Investigation. 2020 Oct 5;130(11). DOI: https://doi.org/10.1172/JCI134915.

Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R. mRNA cancer vaccines. Current Strategies in Cancer Gene Therapy. 2016:61-85.

Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery. 2020 Dec 4:1-24. DOI: https://doi.org/10.1038/s41573-020-0090-8

Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nature reviews Drug discovery. 2014 Oct;13(10):759-80. DOI: https://doi.org/10.1038/nrd4278

Feldman RA, Fuhr R, Smolenov I, Ribeiro AM, Panther L, Watson M, Senn JJ, Smith M, Almarsson Ӧ, Pujar HS, Laska ME. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019 May 31;37(25):3326-34. DOI: https://doi.org/10.1016/j.vaccine.2019.04.074

Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430-6. DOI: https://doi.org/10.1038/s41586-020-2521-4

Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, Rubinstein SM, Lee BJ, Choueiri TK, de Lima Lopes G, Grivas P. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study. Cancer discovery. 2020 Oct 1;10(10):1514-27. DOI: https://doi.org/10.1158/2159-8290.CD-20-0941

Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA oncology. 2021 Feb 1;7(2):220-7. DOI: https://doi.org/0.1001/jamaoncol.2020.6178

Ménétrier-Caux C, Ray-Coquard I, Blay JY, Caux C. Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?. Journal for immunotherapy of cancer. 2019 Dec;7(1):1-5. DOI: https://doi.org/10.1186/s40425-019-0549-5.

Yu JW, Borkowski A, Danzig L, Reiter S, Kavan P, Mazer BD. Immune response to conjugated meningococcal C vaccine in pediatric oncology patients. Pediatric blood & cancer. 2007 Dec;49(7):918-23. DOI: https://doi.org/10.1002/pbc.21174

Goyal S, Pai SK, Kelkar R, Advani SH. Hepatitis B vaccination in acute lymphoblastic leukemia. Leukemia research. 1998 Feb 1;22(2):193-5. DOI: https://doi.org/10.1016/S0145-2126(97)00155-0

Ercan TE, Soycan LY, Apak H, Celkan T, Ozkan A, Akdenizli E, Kasapçopur O, Yildiz I. Antibody titers and immune response to diphtheria-tetanus-pertussis and measles-mumps-rubella vaccination in children treated for acute lymphoblastic leukemia. Journal of pediatric hematology/oncology. 2005 May 1;27(5):273-7. DOI: https://doi.org/10.1097/01.mph.0000163214.37147.5a

Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey G. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. European Journal of Clinical Microbiology and Infectious Diseases. 1993 Oct;12(10):778-82. DOI: https://doi.org/10.1007/BF02098469

Mazza JJ, Yale SH, Arrowood JR, Reynolds CE, Glurich I, Chyou PH, Linneman JG, Reed KD. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clinical medicine & research. 2005 Nov 1;3(4):214-20. DOI: https://doi.org/10.3121/cmr.3.4.214

Nordøy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S, Melby H, Kolstad A. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Medical Oncology. 2002 Jun;19(2):71-8. DOI: https://doi.org/10.1385/MO:19:2:71

Wumkes ML, Van Der Velden AM, Los M, Leys MB, Beeker A, Nijziel MR, van der Velden AW, Westerman M, Meerveld-Eggink A, Rimmelzwaan GF, Rijkers GT. Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours. Vaccine. 2013 Dec 16;31(52):6177-84. DOI: https://doi.org/10.1016/j.vaccine.2013.10.053

Wumkes ML, van der Velden AM, van der Velden AW, Stouthard JM, Nijziel MR, Westerman M, Beeker A, Meerveld-Eggink A, Biesma GR. Influenza vaccination coverage in patients treated with chemotherapy: current clinical practice. Neth J Med. 2013 Nov 1;71(9):472-7.

Chun JY, Kim K, Lee MK, Kang CK, Koh Y, Shin DY, Hong J, Choe PG, Kim NJ, Yoon SS, Park WB. Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients. BMC infectious diseases. 2021 Dec;21(1):1-7. DOI: https://doi.org/10.1186/s12879-021-05806-4

Published

2021-06-20

How to Cite

1.
Rizki Nasution IW, Farhat F, Daulay ER. Covid-19 Vaccination in Nasopharyngeal Carcinoma Patients during COVID-19 Pandemic. IJNPC [Internet]. 2021Jun.20 [cited 2022Aug.15];3(02):45-7. Available from: https://talenta.usu.ac.id/IJNPC/article/view/6323